These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Perfluorodecanoic acid noncompetitively inhibits the peroxisomal enzymes enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase.
    Author: Borges T, Glauert HP, Robertson LW.
    Journal: Toxicol Appl Pharmacol; 1993 Jan; 118(1):8-15. PubMed ID: 8430427.
    Abstract:
    The mechanisms of the inhibition of hepatic peroxisomal beta-oxidation by the peroxisome proliferator PFDA3 were studied. Female Sprague Dawley rats were given a single ip injection of either 0, 10, or 40 mg/kg PFDA or were placed on a diet supplemented with the peroxisome proliferator ciprofibrate (0.01%). After 2 weeks, the rats were killed, and hepatic peroxisomes were isolated by discontinuous sucrose gradient centrifugation. Treatment of rats with either PFDA or ciprofibrate increased the individual activities of each of the enzymes in the peroxisomal beta-oxidation pathway. Similarly, treatment of rats with ciprofibrate greatly increased total peroxisomal beta-oxidation, but peroxisomal beta-oxidation was slightly decreased in rats treated with 40 mg/kg PFDA. In vitro inhibition studies found that PFDA was a noncompetitive and reversible inhibitor of both the activities of the peroxisomal bifunctional protein, namely enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase. The Ki of the inhibition was approximately 5 microM. PFDA only slightly inhibited the activity of peroxisomal fatty acyl CoA oxidase, and did not inhibit peroxisomal thiolase activity. We therefore conclude that PFDA inhibits peroxisomal beta-oxidation by noncompetitively inhibiting the peroxisomal bifunctional enzyme.
    [Abstract] [Full Text] [Related] [New Search]